Fosbretabulin for the treatment of anaplastic thyroid cancer

Future Oncology

Volumn 10, Issue 13, 2014, Pages 2015-2021

  Granata, Roberta ^a   Locati, Laura D ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anaplastic thyroid cancer; Fosbretabulin; Tubulin binding agent

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTRAST ENHANCEMENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LEUKOPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLOOD FLOW; ANIMAL; CHEMISTRY; DRUG SCREENING; PATHOLOGY; THYROID CARCINOMA, ANAPLASTIC;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; STILBENES; THYROID CARCINOMA, ANAPLASTIC;

EID: 84911037757     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/FON.14.154     Document Type: Article

References (24)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual (7th Edition). Springer, NY, USA (2009).
2. Granata R, Locati L, Licitra L. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Curr. Opin. Oncol. 25(3), 224-228 (2013).
3. Smallridge RC, Ain KB, Asa SL et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11), 1104-1139 (2012).
4. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16, 17-44 (2009).
5. Fagin JA. Molecular genetics of human thyroid neoplasms. Annu. Rev. Med. 45, 45-52 (1994).
6. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J. Oncol. 2011, 542358 (2011).
7. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann. Surg. Oncol. 13, 453-464 (2006).
8. Panayiotis S, Govardhanan N, Pierre L et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23(5), 600-604 (2013).
9. Bible KC, Suman VJ, Menefee ME et al. A multiinstitutional Phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 97, 3179-3184 (2012).
10. Mooney CJ, Nagaiah G, Fu P et al. A Phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3), 233-240 (2009).
11. Sosa J, Elisei R, Jarzab B et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 24(2), 232-240 (2014).
12. Ha HT, Lee JS, Urba S et al. A Phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20(9), 975-980 (2010).
13. Woods JA, Hadfield JA, Pettit GR et al. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer 71(4), 705-711 (1995).
14. Dark GG, Hill SA, Prise VE et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57(10), 1829-1834 (1997).
15. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99(6), 2060-2069 (2002).
16. Vincent L, Kermani P, Young LM et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signalling. J. Clin. Invest. 115(11), 2992-3006. (2005).
17. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by tumor specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58, 4510-4514 (1998).
18. Grosios K, Holwell SE, McGown et al. In vivo and in vitro evaluation of combretastatin-A-4 and its sodiumphosphate prodrug. Br. J. Cancer 81, 1318-1327 (1999).
19. Dowlati A, Robertson K, Cooney M et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62, 3408-3416 (2002).
20. Stevenson JP, Rosen M, Sun w et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21(23), 4428-4438 (2003).
21. Rustin GJS, Galbraith SM, Handerson H et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21(15), 2815-2822 (2003).
22. Rustin GJ, Shreeves G, Nathan PD et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br. J. Cancer 102(9), 1355-1360 (2010).
23. Cooney MM, Savvides P, Agarwala SS et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J. Clin. Oncol. 24(18 Suppl.), 5580 (2006).
24. Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer. http://clinicaltrials.gov/show/NCT01305213